Universitätsklinikum Münster

Gender disparity regarding work-life balance satisfaction among German neuro-oncologists: a YoungNOA survey (2022) Kebir S, Lazaridis L, Wick W, Platten M, Tabatabai G, Combs SE, Schmidt T, et al. Journal article Mutations in CFAP74 as a cause of primary ciliary dyskinesia (PCD) with normal nasal NO production rate and normal ciliary ultrastructure (2022) Biebach L, Cindric S, Koenig J, Aprea , Dougherty G, Raidt J, Bracht D, et al. Conference contribution A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST) (2022) Ahrens M, Escudier B, Haanen J, Gross-Goupil M, Boleti E, Gravis G, Grimm MO, et al. Conference contribution Factors associated with long-term survival after failure a chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B-cell lymphomas:a role for allogeneic stem cell transplantation? (2022) Derigs P, Bethge W, Holtick U, Von Tresckow B, Ayuk F, Penack O, Vucinic V, et al. Conference contribution Treatment of patients with advanced urothelial carcinoma in routine care in Germany: initial data from the CARAT-UBC cohort (2022) Goebell P, Mueller L, Boegemann M, Rauh J, Nusch A, Andres-Pons A, Hamm N, et al. Conference contribution Real-world data in children with achondroplasia after licensing of Vosoritide (2022) Palm K, Bechthold-Dalla Pozza S, Gausche R, Hoegler W, Hoyer-Kuhn H, Huebner A, Keller A, et al. Conference contribution Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Meier F, Weichenthal M, Grimmel-Mann I, Gutzmer R, Utikal JS, et al. Conference contribution Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Bluhm L, Grimmelmann I, Gutzmer R, Meier F, Garzarolli M, et al. Conference contribution Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry (2022) Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, et al. Conference contribution Predictors of long-term survival of stage IV melanoma patients: a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG (2022) Placke JM, Mohr P, Bluhm L, Kahler K, Weichenthal M, Meier F, Garzarolli M, et al. Conference contribution